What Drugs Is Ketamine Similar To?

Ketamine's closest pharmacological relative is phencyclidine, better known as PCP. Both belong to a small chemical family called arylcyclohexylamines, and both work primarily by blocking the NMDA receptor in the brain, which is why pharmacologists group them together as dissociative anesthetics. What ketamine is notsimilar to is arguably more useful to know: it's not a benzodiazepine, it's not an opioid, and it's only loosely connected to classic psychedelics like psilocybin or DMT. Each of those comparisons gets made constantly in casual conversation, and each one breaks down once you look at what receptor the drug actually acts on. The rest of this guide walks through each comparison individually, including how ketamine differs from opioids, which is one of the most common mix-ups patients run into.

Ketamine vs. PCP

Ketamine and PCP really do belong to the same drug family. Both are arylcyclohexylamines, both act as NMDA-receptor antagonists, and both were originally developed and studied as anesthetics — PCP first, in the 1950s, with ketamine synthesized in the 1960s specifically as a shorter-acting, better-tolerated alternative. That development history matters: ketamine was designed to fix PCP's biggest clinical problems, particularly its long duration of action and a high rate of severe emergence reactions (confusion, agitation, and hallucinations as the drug wore off).

The practical differences between them are large despite the shared mechanism. Ketamine's effects at anesthetic and subanesthetic doses typically resolve within one to a few hours, while PCP's effects can last considerably longer and are harder to predict. Ketamine has a well-documented medical safety record spanning more than fifty years, FDA approval as a general anesthetic, and current use in monitored clinical settings for depression, pain, and procedural sedation. PCP has no accepted medical use in the United States today and is a Schedule II controlled substance, reflecting a different, higher risk profile than ketamine's Schedule III status. So while the shared mechanism explains why the two get compared, it doesn't mean they carry the same risk or serve the same purpose — the full breakdown of ketamine's drug class and DEA schedule covers how that scheduling gap is determined.

The mechanism itself is worth spelling out, because it's the entire basis for the comparison. NMDA receptors are a subtype of glutamate receptor that normally allow calcium and other ions to flow into a nerve cell when the channel opens. Both ketamine and PCP work as "open-channel blockers" — they physically lodge inside that channel and prevent ion flow, which dampens the excitatory signaling glutamate would otherwise produce. That single shared action is what accounts for the dissociative effects, the analgesia, and much of the abuse-potential profile both drugs carry. It is also why anesthesiologists sometimes pair ketamine with a benzodiazepine such as midazolam during procedural sedation — the benzodiazepine has no effect on the NMDA mechanism itself, but it can blunt the confusion or agitation some patients experience as ketamine wears off, a practice documented in the anesthesia literature for both ketamine and, historically, PCP.

Is Ketamine a Benzodiazepine?

No. Benzodiazepines — drugs like alprazolam (Xanax), diazepam (Valium), and clonazepam (Klonopin) — work by enhancing the activity of GABA-A receptors, the brain's primary inhibitory neurotransmitter system. Boosting GABA signaling is what produces a benzodiazepine's calming, anti-anxiety, and sedative effects. Ketamine doesn't interact with that system in any meaningful way; its defining action is blocking NMDA receptors, an entirely separate glutamate-based pathway.

The confusion between the two usually comes from surface-level overlap rather than mechanism. Both can produce sedation at sufficiently high doses, both are used in medical settings, and both are controlled substances with real dependence potential. But a benzodiazepine calms the nervous system down through GABA enhancement, while ketamine produces dissociation through NMDA blockade — different receptors, different subjective effects, and different withdrawal patterns. Benzodiazepine withdrawal, for example, can be medically dangerous and is managed with a slow taper; ketamine doesn't carry that same withdrawal profile.

The distinction matters clinically, not just semantically. Because the two drug classes act on different receptor systems, they carry different dependence patterns, different withdrawal profiles, and different safeguards during treatment — which is why a prescriber treats "is this like a benzodiazepine?" as a real pharmacological question rather than a matter of labeling.

Ketamine vs. Classic Psychedelics (DMT, Psilocybin) and Ibogaine

Classic psychedelics — DMT, psilocybin, and LSD — work through a largely different mechanism than ketamine. They act mainly as agonists at the serotonin 2A (5-HT2A) receptor, and that receptor activity is what produces the vivid visual and sensory distortions associated with a psychedelic trip. Ketamine's dissociative effects instead come from NMDA receptor blockade, the same target it shares with PCP. Because the receptor systems don't meaningfully overlap, pharmacologists keep dissociatives and serotonergic psychedelics in separate classes, even though both alter perception. For a closer look at that specific comparison, see is ketamine a psychedelic.

The research timeline is part of why the two keep getting linked together. Ketamine's rapid antidepressant effect was documented in controlled studies in the early 2000s, years before the current wave of clinical trials on psilocybin and MDMA-assisted therapy gained momentum. That earlier research helped establish that a fast-acting, glutamate-based mechanism could relieve depression on a timescale of hours rather than the weeks typical antidepressants take — a finding that reshaped how researchers thought about treatment-resistant depression and helped open the door to studying other altered-state compounds, including psilocybin and MDMA, for similar purposes. The two research threads grew up alongside each other, which is a large part of why the drugs themselves get colloquially lumped together even though their receptor targets don't overlap.

Ibogaine sits further outside the comparison still. It has a complex, multi-target pharmacology that touches NMDA receptors, opioid receptors, and serotonin transporters simultaneously, and it's studied and used mainly in the context of interrupting opioid withdrawal and substance-use patterns rather than as a mental-health treatment in the mold of ketamine or psilocybin. It also carries documented cardiac risks that make it considerably higher-risk than ketamine in a monitored medical setting. The reason ketamine, DMT, psilocybin, and ibogaine all get mentioned together in the same conversations isn't shared pharmacology — it's that all four are active areas of mental-health and addiction research exploring fast-acting, non-traditional treatment mechanisms. That research-community overlap is real; the underlying chemistry mostly isn't.

Is Ketamine a Painkiller?

Yes, in a real and clinically useful sense — just not through the mechanism opioids use. Ketamine's NMDA-receptor blockade has genuine analgesic properties, and it's used in some pain clinics for conditions like complex regional pain syndrome and other forms of nerve-related pain that respond poorly to standard treatment. That analgesic effect is well-documented in the anesthesia and pain-medicine literature, separate from its more recently studied use for depression.

Low-dose ketamine infusions are also used inside hospitals for acute pain, including in some emergency departments as an alternative or supplement to opioid analgesia, and in perioperative medicine as part of an "opioid-sparing" strategy meant to reduce how much opioid medication a surgical patient needs. None of that makes ketamine interchangeable with an opioid prescription for everyday pain — its analgesic effect profile, dosing considerations, and administration requirements are different, and it isn't a first-line option for most routine pain. But it is a real, mechanistically distinct tool that pain medicine has used for decades specifically because it doesn't rely on the opioid receptor system at all.

What ketamine is not is an opioid analgesic. Opioids relieve pain primarily by binding to mu-opioid receptors; ketamine's pain relief works mainly through NMDA-receptor blockade instead. Ketamine has only weak direct affinity for opioid receptors, and while researchers are still debating whether the opioid system plays some indirect role in ketamine's antidepressant effect, its analgesia is not opioid-receptor-driven the way morphine's or oxycodone's is. That distinction is a large part of why some prescribers reach for ketamine specifically for patients trying to manage pain without adding to their opioid exposure. It also means ketamine doesn't carry the same respiratory-depression risk that makes opioid overdose so dangerous. If you're trying to place ketamine within the broader map of familiar drug categories — stimulant, depressant, or something else — that question is covered separately in the guide on whether ketamine is an upper or a downer.

If you're researching ketamine as a treatment option rather than trying to place it in a drug-comparison chart, you can browse ketamine clinics near you and review what each one states about the specific treatments, screening, and monitoring they provide.

Frequently Asked Questions

Sources: DEA Controlled Substances Act scheduling records, FDA prescribing information for ketamine and esketamine (Spravato), and peer-reviewed pharmacology literature on NMDA-receptor, GABA-A-receptor, serotonin 2A-receptor, and mu-opioid-receptor mechanisms. Informational only — not medical advice. Talk with a licensed clinician about your health history before starting treatment.